Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 17, 2021

SELL
$9.1 - $19.57 $358,767 - $771,547
-39,425 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$12.02 - $24.71 $254,547 - $523,283
21,177 Added 116.05%
39,425 $709,000
Q3 2020

Nov 13, 2020

BUY
$4.25 - $14.19 $77,554 - $258,939
18,248 New
18,248 $259,000

Others Institutions Holding CRDF

About Cardiff Oncology, Inc.


  • Ticker CRDF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,334,900
  • Market Cap $107M
  • Description
  • Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...
More about CRDF
Track This Portfolio

Track Mirabella Financial Services LLP Portfolio

Follow Mirabella Financial Services LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirabella Financial Services LLP, based on Form 13F filings with the SEC.

News

Stay updated on Mirabella Financial Services LLP with notifications on news.